- Kyle Steiger
appointed Senior Vice-President and Chief Commercial
Officer
- Jean-François Fournier
appointed new Business Unit Head - Ophthalmology
MONTREAL, Aug. 30,
2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH)
(OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"),
a Canadian pharmaceutical company, today announced the appointment
of Mr. Kyle Steiger to the role of
Senior Vice-President and Chief Commercial Officer ("CCO").
Mr. Steiger is a pharmaceutical industry veteran whose diverse
work experience includes specialty pharma, biologics, primary care,
medical devices, OTC, health policy and market access. He spent
nearly 20 years at Novartis Canada in various executive positions
including Franchise Head Hematology, Vice-President Primary Care
and most recently Vice-President Ophthalmology.
"I am very pleased to welcome Kyle to our management team. He
has extensive experience in our core therapeutic areas of focus,
Respiratory and Ophthalmology, and his integrity, passion and
entrepreneurial spirit are a great fit with Valeo's culture", said
Steve Saviuk, CEO. "The recent
addition of Ophthalmic therapies XIIDRA® and SIMBRINZA®, as well as
ALLERJECT® for severe allergic reactions, doubles our existing
revenue base. Within our broad product portfolio, we now have six
drugs expected to produce significant revenue growth across three
therapeutic business units, Respiratory/Allergy, Ophthalmology and
Hospital Specialty. Creating the new position of CCO allows us to
streamline and focus our commercial strategy and
activities."
"Valeo has all the right components in place to become one of
the leading Canadian pharmaceutical companies. We have the right
set of innovative products, the right team of people and
appropriate corporate structure to deliver on our ambitious
corporate objectives. I am thrilled to be joining the company at
such an exciting time and look forward to help accelerating our
growth, profitability, and industry leadership ambitions", said
Kyle Steiger, Valeo's new Chief
Commercial Officer.
Valeo also announced that Mr. Jean-François Fournier has joined as its new Business Unit
Head – Ophthalmology. Prior to joining Valeo, Jean-François
served as Commercial Director – Marketing & Sales at Novartis
Canada.
"Jean-Francois has a strong
background in Ophthalmology and an in-depth knowledge of both
XIIDRA® and SIMBRINZA®. We are pleased to have him assume the
leadership of our new Ophthalmology business unit," continued Mr.
Saviuk.
About Valeo Pharma
Valeo Pharma is a fast growing pharmaceutical company dedicated
to the commercialization of innovative prescription products in
Canada with a focus on
Respiratory/Allergy, Ophthalmology and Hospital Specialty Products.
Headquartered in Kirkland, Quebec
Valeo Pharma has all the required capabilities and the full
infrastructure to register and properly manage its growing product
portfolio through all stages of commercialization. For more
information, please visit www.valeopharma.com and follow us on
LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about
Valeo's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate.
SOURCE Valeo Pharma Inc.